WallStreetZenWallStreetZen

NASDAQ: LEXX
Lexaria Bioscience Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Lexaria Bioscience revenue was $615.92k for the trailing 12 months ending May 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on May 31, 2025 was $174.0k, up 0% from last quarter. For the last reported fiscal year 2024 ending Aug 31, 2024, LEXX annual revenue was $464.3k, with 105.2% growth year-over-year.

LEXX past revenue growth

How has LEXX's revenue growth performed historically?

Company
49.85%
Industry
150.55%
Market
20.43%
LEXX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LEXX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LEXX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

LEXX revenue history

Current Revenue
$615.9k
Current Earnings
-$11.4M
Current Profit Margin
-1,849.4%

Be the first to know when LEXX announces revenue.

LEXX Revenue History By Year

LEXX Yearly RevenueLEXX RevenueLEXX ChangeLEXX Revenue Growth
2024-08-31$464.28k$238.07k+105.24%
2023-08-31$226.21k-$29.19k-11.43%
2022-08-31$255.40k-$467.34k-64.66%
2021-08-31$722.74k$407.95k+129.59%
2020-08-31$314.79k$92.18k+41.41%
2019-08-31$222.61k-$210.68k-48.62%
2018-08-31$433.29k$369.65k+580.85%
2017-08-31$63.64k$22.92k+56.29%
2016-08-31$40.72k$26.02k+176.96%
2015-08-31$14.70kN/AN/A
2014-08-31$0.00N/AN/A
2013-10-31$0.00-$1.36M-100.00%
2012-10-31$1.36M$224.00k+19.76%
2011-10-31$1.13M$771.30k+212.79%
2010-10-31$362.47k-$59.48k-14.10%
2009-10-31$421.96k-$478.83k-53.16%
2008-10-31$900.79k$647.64k+255.83%
2007-10-31$253.15k$232.84k+1,146.60%
2006-10-31$20.31kN/AN/A
2005-10-31$0.00N/AN/A

1 of 2

Lexaria Bioscience Revenue FAQ

What was LEXX's revenue last quarter?

On Invalid Date, Lexaria Bioscience (NASDAQ: LEXX) reported Q2 2025 revenue of $174.00 thousand up 107.14% year over year. In the same quarter last year, Lexaria Bioscience's revenue was $84.00 thousand.

What was Lexaria Bioscience's revenue in 2024?

Lexaria Bioscience's annual revenue for the twelve months ending Aug 31, 2024 was $464.28 thousand, a 105.24% increase year over year.

How much does Lexaria Bioscience make in a day?

Based on Lexaria Bioscience annual revenue for the past five years, LEXX makes an average of $1,086.80 per day.

What was Lexaria Bioscience's annual revenue growth in the past year?

As of Q4 2025, Lexaria Bioscience's revenue has grown 49.85% year over year. This is 100.7 percentage points lower than the US Biotechnology industry revenue growth rate of 150.55%. Lexaria Bioscience's revenue in the past year totaled $615.92 thousand.

How much does Lexaria Bioscience make in a year?

Lexaria Bioscience's revenue by year for the past five years is:
  • Lexaria Bioscience's revenue for the twelve months ending Aug 31, 2024 was $464.28 thousand, a 105.24% increase year over year.
  • Lexaria Bioscience's annual revenue for Aug 31, 2023 was $226.21 thousand, a 11.43% decrease from 2022.
  • Lexaria Bioscience's annual revenue for 2022 was $255.40 thousand, a 64.66% decrease from 2021.
  • Lexaria Bioscience's annual revenue for 2021 was $722.74 thousand, a 129.59% increase from 2020.
  • Lexaria Bioscience's annual revenue for 2020 was $314.79 thousand, a 41.41% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.